Displaying drugs 7851 - 7875 of 8170 in total
ND1251
ND1251 is an orally active phosphodiesterase-4 (PDE4) inhibitor, a mechanism clinically proven to play a role in alleviating symptoms of depression. ND1251 is a very potent compound with a large safety margin. ND1251 may also have applications in other disorders, such as Alzheimer's disease, mild cognitive impairment, multiple sclerosis and...
Investigational
Matched Description: … phosphodiesterase-4 (PDE4) inhibitor, a mechanism clinically proven to play a role in alleviating symptoms of …
Polyvalent antigen-KLH conjugate vaccine
Polyvalent antigen-KLH conjugate vaccine is a multivalent cancer vaccine comprised of the five tumor-associated antigens (TAAs) globo H, GM2 ganglioside, Tn-MUC1, TF, and sTn conjugated with the immunoadjuvant keyhole limpet hemocyanin (KLH). It is under investigation in clinical trial NCT01223235 (Polyvalent Vaccine-klh Conjugate + Opt-821 Given in Combination With Bevacizumab).
Investigational
Matched Description: … Polyvalent antigen-KLH conjugate vaccine is a multivalent cancer vaccine comprised of the five tumor-associated …
N-Methylmesoporphyrin
N-methylmesoporphyrin is a solid. This compound belongs to the porphyrins. These are compounds containing a fundamental skeleton of four pyrrole nuclei united through the alpha-positions by four methine groups to form a macrocyclic structure. This medication is known to target ferrochelatase.
Experimental
Matched Description: … These are compounds containing a fundamental skeleton of four pyrrole nuclei united through the alpha-positions …
Ethanolamine
A viscous, hygroscopic amino alcohol with an ammoniacal odor. It is widely distributed in biological tissue and is a component of lecithin. It is used as a surfactant, fluorimetric reagent, and to remove CO2 and H2S from natural gas and other gases.
Experimental
Matched Description: … It is widely distributed in biological tissue and is a component of lecithin. …
Nitroarginine
An inhibitor of nitric oxide synthetase which has been shown to prevent glutamate toxicity. Nitroarginine has been experimentally tested for its ability to prevent ammonia toxicity and ammonia-induced alterations in brain energy and ammonia metabolites. (Neurochem Res 1995:200(4):451-6)
Experimental
Investigational
Matched Description: … An inhibitor of nitric oxide synthetase which has been shown to prevent glutamate toxicity. …
ADX10059
ADX10059 is a metabotropic glutamate receptor 5 (mGluR5) negative allosteric modulator (NAM). The orally available small molecule drug candidate, which is highly specific for mGluR5, was discovered at Addex in 2003. It is developed for the treatment of GERD, migraine and anxiety.
Investigational
Matched Description: … It is developed for the treatment of GERD, migraine and anxiety. …
INGN 225
INGN 225 is a therapeutic consisting of a cancer patient's own immune cells treated with an adenovector carrying the human p53 gene, Ad-p53. INGN 225 is currently in Phase 1/2 trials in patients with small cell lung cancer and breast cancer.
Investigational
Matched Description: … INGN 225 is a therapeutic consisting of a cancer patient's own immune cells treated with an adenovector …
2'-C-methylcytidine
A nucleoside analog with anti-hepatitis C virus (HCV) activity. Upon phosphorylation into its 5-triphosphate form, this metabolite inhibits viral RNA chain elongation and viral RNA-dependent RNA polymerase activity. This blocks viral production of HCV RNA and thus viral replication.
Experimental
Matched Description: … This blocks viral production of HCV RNA and thus viral replication. …
Sirpiglenastat
Sirpiglenastat, also known as DRP-104, is a prodrug of 6-diazo-5-oxo-L-norleucine (DON), which is a broad-acting glutamine antagonist. It is under investigation in clinical trial NCT04471415 (Study to Investigate DRP-104 in Adults With Advanced Solid Tumors).
Investigational
Matched Description: … Sirpiglenastat, also known as DRP-104, is a prodrug of [6-diazo-5-oxo-L-norleucine] (DON), which is a …
Andecaliximab
Andecaliximab is a monoclonal antibody directed against matrix metallopeptidase 9 (MMP9). Andecaliximab is under investigation in clinical trial NCT03631836 (Phase I Study of Monoclonal Antibondy (GS) 5745, an Matix Metalloproteinase 9 (MMP9) Mab Inhibitor, in Combination With Bevacizumab in Patients With Recurrent Glioblastoma).
Investigational
Matched Description: … Andecaliximab is under investigation in clinical trial NCT03631836 (Phase I Study of Monoclonal Antibondy …
MCC
Mycobacterial Cell Wall-DNA Complex (MCC) is formulated from Mycobacterium phlei, a non-pathogenic strain of mycobacteria. MCC has been shown to have immune stimulatory and apoptosis (programmed cell death) activity against cancer cells. The product is a sterile biological composition in a sub-micron suspension. It is produced at the Bioniche manufacturing...
Investigational
Matched Description: … Mycobacterial Cell Wall-DNA Complex (MCC) is formulated from Mycobacterium phlei, a non-pathogenic strain of …
QR-333
QR-333 has been investigated as a treatment for diabetic peripheral neuropathy. QR-333 is a concentrated and standardized nutrient based active compounds dosed in a topical cream designed to reduce oxidative stress and treat symptoms of Diabetic Peripheral Neuropathy, a nerve disorder that can lead to numbness, skin ulcers, constant pain...
Investigational
Matched Description: … based active compounds dosed in a topical cream designed to reduce oxidative stress and treat symptoms of …
CLX-0921
CLX-0921 is investigated for use/treatment in diabetes mellitus type 2. CLX-0921 is a solid. CLX-0921 has a spectrum of activity that differs from commercially available thiazolidinediones. This substance targets the protein peroxisome proliferator-activated receptor gamma. It is a pharmacologically active antihyperglycemic agent that acts by increasing peripheral tissue sensitivity to...
Investigational
Matched Description: … CLX-0921 has a spectrum of activity that differs from commercially available thiazolidinediones. …
(1E)-5-(1-piperidin-4-yl-3-pyridin-4-yl-1H-pyrazol-4-yl)-2,3-dihydro-1H-inden-1-one oxime
(1E)-5-(1-piperidin-4-yl-3-pyridin-4-yl-1h-pyrazol-4-yl)-2,3-dihydro-1h-inden-1-one oxime is a solid. This compound belongs to the phenylpyrazoles. These are compounds containing a phenylpyrazole skeleton, which consists of a pyrazole bound to a phenyl group. It targets the protein serine/threonine-protein kinase B-raf.
Experimental
Matched Description: … These are compounds containing a phenylpyrazole skeleton, which consists of a pyrazole bound to a phenyl …
Dexchlorpheniramine
Dexchlorpheniramine is a potent S-enantiomer of chlorpheniramine. The salt form dexchlorpheniramine maleate as the active ingredient is available as a prescription drug indicated for adjunctive therapy for allergic and anaphylactic reactions. It is an antihistamine drug with anticholinergic (drying) and sedative actions. It disrupts histamine signaling by competing with histamine...
Experimental
Investigational
Matched Description: … Dexchlorpheniramine is a potent S-enantiomer of chlorpheniramine. …
BNT162c2 SARS-CoV-2 Vaccine
BNT162c2 is one of four advanced mRNA-based vaccines being developed through "Project Lightspeed," a joint program between Pfizer and BioNTech.[L15002, L15007] BNT162c2 is a self-amplifying mRNA (saRNA) vaccine formulated in lipid nanoparticles for delivery via intramuscular injection.[L15002, L15007]
BNT162c2 is undergoing evaluation in clinical trials in both the USA (NCT04368728)...
Investigational
Matched Description: … BNT162c2 is one of four advanced mRNA-based vaccines being developed through "Project Lightspeed," a …
D-Glutamine
A non-essential amino acid present abundantly throughout the body and is involved in many metabolic processes. It is synthesized from glutamic acid and ammonia. It is the principal carrier of nitrogen in the body and is an important energy source for many cells.
Experimental
Matched Description: … It is the principal carrier of nitrogen in the body and is an important energy source for many cells. …
Zebularine
A chemically stable, cytidine analog that displays anti-tumor properties. It acts as a transition state analog inhibitor of cytidine deaminase by binding to the active site as covalent hydrates. Also shown to inhibit DNA methylation and tumor growth both in vitro and in vivo.
Experimental
Matched Description: … It acts as a transition state analog inhibitor of cytidine deaminase by binding to the active site as …
IR208
IR208 is a synthetic T-Cell receptor peptide
vaccine developed by Immune Response Corporation.
It contains three peptides (BV5S2, BV6S5
and BV13S1) expressed by T-Cells in over 90% of MS
patients. IR208 is currently undergoing Phase II
studies in a 200-patient trial.
Investigational
Matched Description: … It contains three peptides (BV5S2, BV6S5
and BV13S1) expressed by T-Cells in over 90% of MS
patients …
Pimagedine
Pimagedine has been developed by Synvista Therapeutics, Inc for the treatment of diabetic kidney disease. It is an advanced glycation end product inhibitor which manages diabetic nephropathy, either alone or in combination with other therapies. It is beneficial in treating patients with diabetic nephropathy.
Investigational
Matched Description: … Pimagedine has been developed by Synvista Therapeutics, Inc for the treatment of diabetic kidney disease …
IMC-1C11
IMC-1C11 is an anti-angiogenesis agent. It is a chimeric anti-kinase insert domain-containing receptor (KDR) antibody that blocks VEGFR-KDR interaction and inhibits VEGFR-induced endothelial cell proliferation. IMC-1C11 is used for treatment of patients with liver metastases from colorectal carcinoma.
Investigational
Matched Description: … IMC-1C11 is used for treatment of patients with liver metastases from colorectal carcinoma. …
Selisistat
Selective inhibitor of SIRT1 that does not inhibit histone deacetylase (HDAC) or other sirtuin deacetylase family members (IC50 values are 98, 19600, 48700, > 100000 and > 100000 nM for SIRT1, SIRT2, SIRT3, HDAC and NADase respectively). Enhances p53 acetylation in response to DNA damaging agents.
Experimental
Matched Description: … Selective inhibitor of SIRT1 that does not inhibit histone deacetylase (HDAC) or other sirtuin deacetylase …
AdimrSC-2f
The AdimrSC-2f (SARS-CoV-2) vaccine is developed through Adimmune Corporation, the only influenza vaccine manufacturer with both EU GMP and US FDA certification in Asia . A phase I study (NCT04522089) will investigate the safety and immunogenicity of the vaccine[L30553, L30548].
Investigational
Matched Description: … A phase I study (NCT04522089) will investigate the safety and immunogenicity of the vaccine[L30553, L30548 …
CYC116
CYC116 is a novel anticancer compound with a unique target profile involving both cell cycle and angiogenesis inhibition mechanisms. In preclinical studies, CYC116 has demonstrated antitumor activity in both solid tumors and hematological cancers.
Cyclacel's small molecule investigational drug, CYC116, is the third orally-available Cyclacel drug to enter development, which...
Investigational
Matched Description: … enter development, which demonstrated anticancer activity with a mechanism consistent with inhibition of …
OPC-28326
At low doses, OPC 28326 selectively vasodilates the femoral arterial bed due to its inhibitory action at alpha-2-adrenoceptors while having minimal action on systemic blood pressure, heart rate and coronary, carotid, vertebral, renal, and mesenteric blood flows. It is the only clinical compound with this profile. It is currently being...
Investigational
Matched Description: … It is currently being investigated in the treatment of peripheral vascular diseases and Raynaud's syndrome …
Displaying drugs 7851 - 7875 of 8170 in total